We are pleased to share that the research of Gibela Therapeutics, our portfolio company, was featured on the cover of the Hepatology journal.
The company is developing an innovative RNA-based therapy that focuses on modulating mitochondrial activity and endoplasmic reticulum stress—two key hub processes in liver disease pathogenesis.
Gibela’s research originates from the lab of Dr. Malu Martínez-Chantar at Cooperative Research Center in Biosciences (CIC bioGUNE). In this paper, they shed light on the dysregulation of Mg2+ homeostasis in alcohol-associated liver disease, providing a promising therapeutic approach targeting CNNM4. N-acetylgalactosamine siCnnm4 therapy boosts the repair processes of ethanol-damaged proteins through the upregulation of PCMT1 activity.
Gibela Therapeutics is actively advancing its pipeline to target both high-prevalence liver diseases and those with lower incidence, with a strong emphasis on personalized medicine.
Congratulations to the whole team on this achievement!
Read the publication here.
